Screener
Recursion Pharmaceuticals, Inc. RXRX Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Recursion Pharmaceuticals, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 6:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001601830-26-000098
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Purchase of an intangible asset | — | (3,000) |
| Net cash provided by (used in) financing activities | (4,737) | 138,186 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (3,019) | 14,088 |
| Net change in cash, cash equivalents and restricted cash | (197,101) | (69,179) |
| Cash, cash equivalents and restricted cash, beginning of period | 753,921 | 603,024 |
| Cash, cash equivalents and restricted cash, end of period | $556,820 | $533,845 |
| Supplemental schedule of non-cash investing and financing activities | ||
| Accrued property and equipment | 300 | 263 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Recursion Pharmaceuticals, Inc.'s net change in cash?
- Recursion Pharmaceuticals, Inc. (RXRX) reported net change in cash of -$108.36M in Q2 2026.
- How has Recursion Pharmaceuticals, Inc.'s net change in cash changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s net change in cash decreased by 538.9% year-over-year, from $24.69M to -$108.36M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Recursion Pharmaceuticals, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude